On May 11, 2026, the Centers for Disease Control and Prevention's World Trade Center Health Program formally announced the denial of three petitions to add peripheral neuropathy to its roster of covered health conditions. This determination, issued by the Administrator of the WTC Health Program, follows an extensive scientific review and means that individuals suffering from peripheral neuropathy, believed by some to be linked to 9/11 exposures, will not currently receive medical monitoring or treatment benefits under the program for this specific condition. The decision underscores the meticulous, evidence-based process governing additions to the critical program.
Establishing the WTC Health Program Framework
The World Trade Center Health Program operates under Title I of the James Zadroga 9/11 Health and Compensation Act of 2010, which amended the Public Health Service Act. Established within the Department of Health and Human Services, the program provides medical monitoring and treatment for health conditions on its official List of WTC-Related Health Conditions. Beneficiaries include eligible firefighters, law enforcement, rescue, recovery, and cleanup workers—referred to as responders. This also includes survivors who were present in the dust cloud or lived or worked in the New York City disaster area following the September 11, 2001, terrorist attacks. The Administrator of the program, effectively the Director of the National Institute for Occupational Safety and Health, has the statutory authority to add conditions to this list based on scientific evidence.
The Rigorous Petition and Evaluation Process
The PHS Act outlines a specific procedure for adding new health conditions. Interested parties can petition the Administrator, who then has 90 days to take one of four actions: request a recommendation from the WTC Health Program Scientific/Technical Advisory Committee, publish a proposed rule to add the condition, publish a determination not to publish a proposed rule, or publish a determination that insufficient evidence exists to take further action. A petition must present a sufficient medical basis for an association between 9/11 exposures and the proposed health condition, often through peer-reviewed epidemiologic studies or clinical case reports. For conditions previously evaluated and denied, a new petition requires a new medical basis, meaning evidence not previously reviewed.
Once a petition is deemed valid, the WTC Health Program Science Team undertakes a comprehensive review of scientific literature. This involves a keyword search of relevant databases to identify peer-reviewed epidemiologic studies concerning the health condition among 9/11-exposed populations. The Science Team meticulously evaluates the scientific quality of these studies using validity indicators. Studies meeting high-quality standards are then assessed individually and collectively. This characterizes the evidence of a causal association between 9/11 exposures and the health condition. This evaluation incorporates the Bradford Hill weight of evidence criteria. These criteria consider aspects such as strength, consistency, and biological plausibility of association. Study limitations and representativeness of the 9/11-exposed population are also considered.
Categorizing Scientific Evidence
Following this rigorous assessment, the Science Team assigns the evidence to one of five categories:
- Category I: Evidence supports substantial likelihood of causal association.
- Category II: Evidence supports high likelihood of causal association.
- Category III: Evidence supports limited likelihood of causal association.
- Category IV: Evidence does not support causal association.
- Category V: Evidence is inadequate to determine the likelihood of causal association.
A health condition can be added to the List only if the evidence reaches Category I. If the evidence falls into Category II, the Administrator may consider additional scientific evidence. This additional evidence would relate to 9/11 agents in non-9/11 exposure scenarios. If this additional assessment then elevates the conclusion to Category I, the Administrator may propose the condition for addition.
The Denial of Peripheral Neuropathy Petitions
The recent denial specifically addresses Petitions 032, 033, and 068, all seeking to add peripheral neuropathy to the List. Petition 032, received on July 29, 2021, requested inclusion of "neuropathy and paresthesias." The Program interpreted this as peripheral neuropathy because paresthesia is a symptom. This petition's validity was initially established by a peer-reviewed epidemiologic study by Marmor M, et al. [2020]. This study, a case-control analysis, identified an increased prevalence of clinical and laboratory-test abnormalities. These abnormalities indicated neuropathy among individuals with WTC exposure and paresthesia of the lower extremities. Petition 033 was received on September 2, 2021, and also requested the addition of peripheral neuropathy. The provided text ends before detailing Petition 068. However, it states the denial applies to all three.
After reviewing the scientific and medical literature, including information from the petitioners, the Administrator concluded there was insufficient evidence to support taking further action. This means the collective evidence for peripheral neuropathy did not meet the stringent Category I threshold for "substantial likelihood of causal association" nor did it meet Category II, which would have prompted further consideration. Consequently, the Administrator found insufficient evidence to request a recommendation from the STAC, publish a proposed rule, or even publish a determination not to publish a proposed rule. The May 11, 2026, decision thus represents a definitive denial based on the current body of scientific evidence.
Implications and Future Outlook
The denial of peripheral neuropathy petitions highlights the high evidentiary bar set by the WTC Health Program. While the Marmor et al. study helped validate one petition, it, along with other reviewed literature, evidently did not collectively establish a "substantial likelihood" of a causal association as defined by the program's policies. For 9/11 responders and survivors experiencing peripheral neuropathy, this means the condition is not currently covered for treatment or monitoring benefits. This decision does not preclude future reconsideration if new medical evidence emerges. A new petition with a genuinely new medical basis, not previously reviewed, could potentially trigger another evaluation process. The program's commitment to scientific rigor ensures that its List of covered conditions remains firmly rooted in established causal links, a critical aspect of its integrity and long-term sustainability.
